Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis

Overview

The purpose of this study is to determine if celiac bloc (with injection of steroid and local anesthetic) is superior to a sham procedure for pain control and quality of life improvement in patient with chronic pancreatitis and abdominal pain.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: June 14, 2019

Detailed Description

Chronic pancreatitis is a condition that can lead to very disabling pain symptoms that are difficult to control. The use of morphine is often necessary and also induces a series of secondary symptoms. In this context, the injection into the celiac plexus block of a local anesthetic has often been proposed as an alternative. This procedure, by interrupting the afferent pain signal of pancreatic origin, aims to reduce pain and improve quality of life at the cost of fewer side effects. This procedure can be performed transcutaneously using the anatomical landmark or under radiological control. It can also be performed via endosonography (EUS) with better control of the injection site under ultrasound control. The results of the literature concerning the efficacy of the celiac block in chronic pancreatitis are rather encouraging with reported figures of partial or complete pain control in 39 to 65% of patients [1-7]. However, the number of prospective studies concerning this technique performed endoscopically remains low to date. In particular, there are no case control studies. Data is also poor on the impact on quality of life. The study proposed here will therefore attempt to provide answers to the questions still pending: is the block by EUS superior to a diagnostic EUS without treatment? ; how long does this treatment last? ; does it have an impact on the quality of life of patients? This study and its draft are inspired by a similar recent study conducted in our department on patients with pancreatic neoplasia. The results of the latter are being submitted for publication.

Interventions

  • Drug: EUS procedure with drug injection
    • EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
  • Other: EUS procedure
    • EUS procedure without any drug injection

Arms, Groups and Cohorts

  • Experimental: Celiac bloc
    • The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
  • Sham Comparator: Conservative treatment
    • Subject will undergo standard EUS without any additional interventions.

Clinical Trial Outcome Measures

Primary Measures

  • Pain reduction on Likert scale
    • Time Frame: each month for six months
    • Pain scale with 7 levels

Secondary Measures

  • Quality of Life (QOL) score
    • Time Frame: each month for six months
    • the digestive disease QOL questionnaire 15 (DDQ-15) is used to analyze QOL

Participating in This Clinical Trial

Inclusion Criteria

  • abdominal pain compatible with pancreatic ethiology since at least 3 months – chronic pancreatitis on Computed Tomography (CT), Endoscopic Retrograde Cholangiopancreatography (ERCP) or EUS – EUS feasible – inform consent Exclusion Criteria:

  • pregnant women – allergy to local anesthetic – acute pancreatitis in the last 2 weeks – suspicious lesion on pancreatic EUS examination – celiac bloc in the last 3 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre hospitalier de l’Université de Montréal (CHUM)
  • Collaborator
    • Centre de Recherche du Centre Hospitalier de l’Université de Montréal
  • Provider of Information About this Clinical Study
    • Principal Investigator: A Sahai, Gastroenterologist – Centre hospitalier de l’Université de Montréal (CHUM)
  • Overall Official(s)
    • Anand V Sahai, MD, Principal Investigator, CHUM

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.